Adicet Bio, Inc. (ACET)

Market Cap	89.22M +45.9%
Revenue (ttm)	n/a
Net Income	-116.80M
EPS	-16.95
Shares Out	10.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,875
Open	8.22
Previous Close	8.06
Day's Range	8.15 - 8.30
52-Week Range	6.01 - 17.44
Beta	1.58
Analysts	Strong Buy
Price Target	48.33 (+482.29%)
Earnings Date	May 6, 2026

About ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1947
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: ACET
• Website: https://www.adicetbio.com

Analyst Summary

According to 3 analysts, the average rating for ACET stock is "Strong Buy." The 12-month stock price target is $48.33, which is an increase of 482.29% from the latest price.

Price Target

$48.33

(482.29% upside)

Analyst Consensus: Strong Buy